Novo Nordisk A/S (NVO) — closed signal from May 18, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 16, 2026.
Predicted vs. what happened
NVO price · publication thesis → realized outcomesplit-adjusted
$42.70 – $44.07Entry zone — fair-value band
$44.36Published — price the day we called it
$47.31Target — the price the thesis aimed for
$51.46Peak — highest point inside the window, not a realized return
$45.31Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 43 days.
Peak price
$51.46
peak on July 29, 2026 — not a realized returnPeak gain
+16%
peak, from the publication priceWindow close
$45.31
end-of-window price, context onlyDays to target
43
Window
May 18, 2026 – August 16, 2026
The thesis — published May 18, 2026
Predicted growth
+8%
over the measurement windowTarget price
$47.31
the price the thesis aimed forEntry zone
$42.70 – $44.07
the fair-value band we waited forPrice at publication
$44.36
published May 18, 2026Confidence
67%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novo Nordisk is seen as a defensive healthcare pick for the next few months. Buybacks, steady diabetes and obesity product demand, and solid profits make the stock more stable in volatile markets. Near-term upside looks limited after mixed results and a mildly extended chart, so expectation is resilience rather than a big short-term jump.
Primary drivers
- Share buybacks give direct support to returns
- Diabetes and obesity products show steady demand
- High profitability cushions against weak near-term upside
- Low volatility makes it steadier in choppy markets
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.